TTR, independently of other covariates. The interaction test showed that, regarding tumor location (distal versus proximal), KRAS genotype affects differently on recurrence (P = 0.02) and DFS (P = 0.042). Subgroup analysis showed that KRAS only affected TTR and DFS in distal tumors (n = 1043; 692 wild type; 351 mutated), with an increased risk of relapse (HR 1.96, 95% CI 1.51-2.56; P < 0.0001) for KRAS codon 12 mutations and a borderline significance for codon 13 mutations (HR 1.59, 95% CI 1.00-2.56; P = 0.051).
Conclusion: KRAS exon 2 mutations are independent predictors of shorter TTR in patients with resected stage III distal colon cancers receiving adjuvant therapy. Future clinical trials in the adjuvant setting should consider both the tumor location and KRAS mutations as important stratification factors.
Clinical trial number: This is an ancillary study of the PETACC8 trial: EUDRACT 2005-003463-23.
Key words: colorectal cancer, KRAS mutation, cetuximab, proximal colon, distal colon, prognosis introduction Colorectal cancer (CRC) is the fourth cause of cancer death worldwide [1, 2] . Despite advances in drug therapy and the use of targeted treatments [3, 4] , many patients with completely resected cancers still die of metastatic relapses, reflecting a biological heterogeneity, which is not fully understood.
CRC occurs through a multistep process driven by the accumulation of genetic alterations, of which KRAS activating mutations are considered one of the earliest [5] . They are present in ∼45% of CRCs and exclusive of other genetic alterations in EGFR pathway activators such as BRAF and NRAS. KRAS mutations at codons 12 and 13 are the most frequent alterations in CRC, representing more than 90% of all mutations [6] . KRAS status was shown to be a predictive marker of resistance to EGFR inhibitors, leading to restricted use of these drugs in patients with KRAS wild-type metastatic CRC [7] [8] [9] . In contrast, the influence of KRAS mutations on outcome is less evident. In resected colon cancer patients, KRAS mutational status has been linked to disease recurrence and poorer overall survival in recent large prospective cohorts and clinical trials but discrepancies remain [10] [11] [12] . In BRAF wild-type CRC, a poor prognosis was either related to KRAS mutations or restricted to patients with codon 12 mutated tumors [11, [13] [14] [15] .
This post hoc study of the PETACC8 [16] phase III trial analyzed the impact of individual KRAS mutations on time to recurrence (TTR) and disease-free survival (DFS) in stage III CRC patients undergoing surgery and standard 5-fluorouracil (5-FU) and oxaliplatin-based adjuvant therapy and refined the results according to tumor location.
materials and methods

patient characteristics
Patients from the PETACC8 trial had completely resected, histologically proven stage III colon adenocarcinoma and were randomized to receive, as adjuvant treatment, either 6 months of FOLFOX 4 or FOLFOX 4-cetuximab [16] . The trial started in December 2005, it was amended in June 2008 to enroll patients with KRAS wild-type tumors. Written informed consent was required for patients' participation to the PETACC8 planned translational program.
DNA extraction and mutation analysis
Tumor DNAs were extracted from formalin-fixed and paraffin-embedded (FFPE) tissues using the QIAamp® DNA Mini Kit (Qiagen®). Molecular analysis was centralized and carried out retrospectively for 2096 patients included before trial amendment, and prospectively for the other 463 patients, by real-time PCR using TaqMan® probes (Applied Biosystems) for KRAS (c.34G > A/p.G12S, c.34G > C/p.G12R, c.34G > T/p.G12C, c.35G > A/ p.G12D, c.35G > C/p.G12A, c.35G > T/p.G12V and c.38G > A p.G13D) and BRAF (c.1799T > A/p.V600E). Each assay was validated to detect 10% of mutated alleles [17] .
statistical analysis
Patients were divided into two groups: group 1 with mutant KRAS/BRAF and group 2 with wild-type KRAS/BRAF. Comparisons of patients with specific mutations versus the wild-type population only concerned mutations representing more than 10% of all mutations detected this study. The end points for these analyses were TTR and DFS. TTR was defined as the time between the date of randomization and the date of local or metastatic recurrence. DFS was defined as the time between the date of randomization and the date of local or metastatic recurrence, second colon cancer or death, whichever occurred first. Overall survival data are not yet available for the PETACC8 trial and were thus not reported in this work.
For comparisons of baseline characteristics, categorical outcomes were analyzed with χ 2 tests and continuous outcomes were compared with standard parametric or nonparametric tests. Continuous variables are presented as the mean (SD) and median interquartile range. TTR and DFS curves were estimated with the Kaplan-Meier method. Differences between groups of patients were analyzed using unstratified logrank tests. An unstratified Cox regression model was used to estimate hazard ratios (HRs), 95% confidence intervals (CIs) and P values for candidate prognostic factors. Factors included in the multivariate analyses were the treatment group, baseline variables imbalanced between the two PETACC8 arms, and prognostic factors identified in univariate analyses. The WHO 6th edition criteria were used for tumor staging.
Analyses were carried out according to the intention-to-treat principle with a two-sided significance level of 5%. Results were unadjusted for multiple comparisons. All statistical analyses were done with the SAS statistical software package (version 9.4).
results
study population
Among the 2559 patients included in the PETACC8 phase III study, 1810 met all the criteria for molecular analysis (informed consent and available FFPE sample, no technical failure for KRAS/BRAF status determination), 153 were BRAF-mutated and excluded because of the prognostic impact of BRAF mutations ( Figure 1 ), 1 tumor was KRAS-and BRAF-mutated and was also excluded of the analysis. Demographic and clinical characteristics of the patients in the KRAS molecular study (n = 
KRAS results
Of the 1657 tumors, 38.5% had a KRAS mutation, located on codon 12 in 79% of the cases. Detailed repartition is shown on Figure 2A . KRAS mutations were more frequent in women, in proximal CRC, and were associated with age, and no vascular or lymphatic infiltration (Table 1) .
outcome predictors
In the PETACC8 trial, KRAS-mutated tumors were equally numerous in both treatment arms. Moreover, an interaction test was carried out between KRAS status (WT, codon 12 and codon13) and treatment (TTR P = 0.37; DFS P = 0.32) leading to the conclusion that both arms could be pooled to study the impact of KRAS mutations on TTR and DFS. Median follow-up was 3.4 years (95% CI 3.3-3.4) and 3.8 years (95% CI 3.8-3.9) for patients with wild-type and mutated tumors, respectively. TTR was significantly shorter (HR 1.56, 95% CI 1.28-1.92; P < 0.001) in KRAS-mutated patients ( Figure 2B) , with a higher rate of relapse (30% versus 19%, P < 0.001). Codon 12 alterations (HR 1.67, 95% CI 1.35-2.04) but not the p.G13D mutation (HR 0.81, 95% CI 0.56-1.17) were associated with shorter TTR ( Figure 2C ). Figure 2D summarizes the impact of individual mutation on TTR.
In univariate analysis, high-grade tumors (P = 0.0001); stage pT4 (P = 0.0006); stage pN2 (P < 0.0001); obstruction or perforation (P = 0.0001); vascular embolism and/or lymphatic invasion (P = 0.015); KRAS mutations (P < 0.0001) and KRAS codon 12 mutations (P < 0.0001) were all associated with shorter TTR (supplementary Data S2, available at Annals of Oncology online). In multivariate analysis including all significant variables, KRAS mutations (P < 0.001), high-grade tumors (P = 0.012), pT4 (P = 0.009) and pN2 (P < 0.001) remained associated with shorter TTR (Table 2) . Similar results were obtained for DFS (supplementary Data S3-S5, available at Annals of Oncology online).
subgroup analysis
We looked for a different impact of KRAS mutations on TTR and DFS between men and women. The results showed that KRAS codon 12 alterations were related to shorter TTR in both women and men (respectively, HR 1.78, 95% CI 1.29-2.46; P = 0.0004 and HR 1.58, 95% CI 1.19-2.09; P = 0.001).
In proximal cancer, KRAS mutations were more frequent than in distal cancer, with a higher proportion of p.G13D and p. G12D alterations ( Figure 3A ) but had no impact on TTR (HR 1.29, 95% CI 0.90-1.84; NS; HR 0.89; 95% CI 0.50-1.59; NS) ( Figure 3B ). At the opposite, codon 12 alterations (HR 1.96, 95% CI 1.51-2.56; P < 0.0001) were associated with shorter TTR in patients with distal tumors and a trend was found for codon 13 (HR 1.59, 95% CI 1.00-2.56; P = 0.051) ( Figure 3B ). The interaction tests between KRAS mutation status and tumor location on TTR (P = 0.02) and DFS (P = 0.042) and between KRAS WT, codon 12 mutations, p.G13D and location on TTR (P = 0.01) and DFS (P = 0.01), were all positive. Finally, an interaction test was carried out and we could not find a survival effect of p.G13D mutation when compared with p.G12X for TTR (HR 0.75; 95% CI 0.52-1.08; NS) or DFS (HR 0.78; 95% CI 0.55-1.10; NS). Figure 3C summarizes the impact of individual mutation on TTR in both locations.
discussion
We genotyped tumors from 1810 patients enrolled in a randomized phase III trial for KRAS exon 2 and BRAF mutations. The impact of KRAS mutations on TTR and DFS was studied excluding samples with BRAF mutations (8.45%), given that BRAF status itself affects the prognosis. The detection method used for genotyping was validated through various external quality control programs (European Society of Pathology KRAS EQA schemes). As expected in CRC (COSMIC database), KRAS exon 2 mutations were located at codons 12 and 13 in 79% and 21% of the samples, respectively.
Large population-based cohorts restricted to nonmetastatic CRC patients have yielded to different results concerning the prognostic value of KRAS mutations [11-13, 18, 19] . For example, no association between KRAS mutations and relapse or survival was found in the PETACC-3 trial among 1404 CRC patients treated with 5-FU +/− irinotecan [12] . In contrast, the Quasar study [20] , which mainly included stage II patients, showed an increased risk of recurrence among KRAS-mutated patients, which was not affected by adjuvant chemotherapy. The RASCAL population-based studies [13, 14] showed that KRAS p.G12V only, was associated with poorer outcome and Imamura et al. found that codon 12 but not codon 13 (HR 1.25; 95% CI 0.85-1.84; NS) mutations negatively affected cancer specific mortality [11] . In contrast, data from the NCCTG NO147 trial, which had a similar design to PETACC-08, showed that KRAS mutations at codons 12 (HR 1.52; 95% CI 1.28-1.8; P < 0.0001) and codon 13 (HR 1.36, 95% CI 1.04-1.72; P = 0.025) had a prognostic value [21, 22] . This may be due to the heterogeneity of the study populations, which included colon and rectal cancer, stage I-III tumors, patients receiving or not adjuvant treatments, patients with and without BRAF mutations and data from population-based cohorts or from clinical trials. In PETACC8 patients (n = 1657), KRAS codon 12 mutations were related to shorter TTR and DFS. Subsequently, we studied the impact of KRAS mutations on TTR and DFS according to tumor location [23] . Proximal tumors were more frequently KRAS-mutated than were distal tumors. Previous studies also reported higher KRAS mutation rates in proximal when compared with distal colon cancer [12, 23] , but the relationship between cancer location, KRAS status and outcome remains unclear [23] [24] [25] . Here, no effect of KRAS mutations was found for proximal tumors. In contrast, codon 12 alterations had a negative impact on TTR in patients with distal tumors and although the test did not reach statistical significance for p.G13D (P = 0.051), there was a clear trend for a similar effect. This borderline significance is possibly due to the poor number of events and patients in this subgroup. Larger series are needed to definitely state on the prognostic impact of p.G13D in colon tumors. One limitation of our study is that MMR status was not available for patients enrolled in the PETACC8 trial. Deficient MMR phenotype tumors are mainly located in the proximal colon, associated with low recurrence rates, BRAF mutations and KRAS p.G13D [26] [27] [28] . We estimated that more than 50% of MSI-H cancers (10-15% of CCR) were excluded through the exclusion of BRAF-mutated cancers that tends to limit the possible confounding role of MSI status in our series and suggests that our results, by approximation refer to an MSS population. Distal  WT  G12A  G12C  G12D  G12S  G12R  G12V  G13D   WT  G12A  G12C  G12D  G12S  G12R  G12V 
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Another limitation is the lack of data on rare KRAS and NRAS mutations. In a small cohort of patients, KRAS exon3/4-and NRAS-mutated tumors were associated to a better prognostic when compared with exon 2 alterations [29] but large prospective series are still needed to validate the prognostic impact of rare KRAS an NRAS alterations in CCR.
In conclusion, we show in a series of stage III CCR patients included in a randomized, controlled phase III trial that codon 12 KRAS mutations have a significant impact on the TTR in distal CRC. The impact of the p.G13D mutation needs to be refined in a larger series according to tumor location and tumor phenotype (MSS/MSI) although this study suggests that p.G13D distal CRC might behave as p.G12X tumors. Future clinical trials in stage III colon cancer should consider both the tumor location and KRAS mutational status as important stratification factors.
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